HMED.ST
HANSA MEDICAL: HANSA MEDICAL TO PRESENT IdeS AT THE 2014 WORLD TRANSPLANT CONGRESS IN SAN FRANCISCO, JULY 27
Hansa Medical will present the drug candidate IdeSs potential as a
novel treatment for desensitization prior to kidney transplantation,
at the poster session on July 27 at the 2014 World Transplant
Congress in San Francisco, USA.
The World Transplant Congress gathers international experts on
transplantation, attracts prominent keynote speakers as well as
pharmaceutical and biotechnology companies committed to the
improvement of treatment of transplantation patients.
For more information about the World Transplant Congress, please
visit: www.wtc2014.org
The poster presentation will emphasize IdeS antibody deactivating
effect and safety, demonstrated in a recently concluded Phase I study
in healthy volunteers as well as in sera from sensitized patients
pre-kidney transplantation.
More on IdeS
Hansa Medicals drug candidate IdeS is developed as a fast, safe and
expedient method to deactivate IgG-antibodies in sensitized patients
prior to kidney transplantation. For sensitized patients,
IgG-antibodies pose the primary obstacle for a transplant, forcing
patients into years of treatment in dialysis. A successful Phase
I-study was finalized in January 2014 and a Phase II study is planned
for 2014 in sensitized patients awaiting kidney transplantation.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com
